In April 2026, the FDA approved Foundayo™ (orforglipron) — Eli Lilly's once-daily pill for chronic weight management, and the first GLP-1 weight-loss medication you can take any time of day with no food or water restrictions. It's a genuinely new option in a category that has been injection-first, and search interest has exploded since approval.
Pallas now prescribes and dispenses Foundayo™ when a US-licensed clinician determines it's appropriate (cash-pay; not billed to insurance). This explainer exists because patients and readers keep asking about it, and there's a lot of confusion — and some outright misinformation — circulating. Here's what it is, what the evidence shows, and what to watch out for.
Foundayo at a glance
Orforglipron, made by Eli Lilly. FDA-approved April 2026 for adults with obesity, or overweight with at least one weight-related condition, alongside a reduced-calorie diet and increased activity. One tablet daily — no injections, no refrigeration, and no rules about taking it on an empty stomach. Prescription only.
What Foundayo is and how it works
Foundayo™ works the same way the injectable GLP-1 medications do: it activates the GLP-1 receptor, which reduces appetite, slows stomach emptying, and helps regulate blood sugar. The difference is chemistry. The injectable GLP-1s — semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®) — are large, fragile molecules that digestion would destroy, which is why they're injected. Orforglipron is a small-molecule drug: chemically sturdy enough to survive the digestive tract, absorb reliably as a tablet, and skip the cold chain entirely.
That's what makes it different from the oral semaglutide tablets that came before it. Rybelsus® (approved for type 2 diabetes, not weight management), the Wegovy® pill (25 mg tablets, approved in December 2025 for chronic weight management) and Ozempic® tablets (approved in 2026 for type 2 diabetes) must be taken on an empty stomach with a small sip of water, then a 30-minute wait before eating. Foundayo™ has none of those restrictions — any time of day, with or without food.
What the trials showed
In ATTAIN-1, the 72-week trial behind the approval, adults with obesity (without diabetes) taking Foundayo™ 17.2 mg once daily lost an average of 11.1% of their body weight, versus 2.1% on placebo (8.3% at 9 mg; 7.4% at 5.5 mg), alongside a reduced-calorie diet and increased activity. In ATTAIN-2, adults with obesity and type 2 diabetes lost 9.6% at 17.2 mg versus 2.5% on placebo. The most common side effects were gastrointestinal — nausea, constipation, vomiting — the familiar GLP-1 profile, and doses are stepped up gradually to manage them.
For context: in their own separate trials, the FDA-approved injectables produced larger average losses — 14.9% for Wegovy® at 2.4 mg weekly in STEP 1 (18.7% at 7.2 mg in STEP UP) and 20.9% for Zepbound® at 15 mg weekly in SURMOUNT-1 — and the Wegovy® pill produced 13.6% at 25 mg daily in OASIS 4. Those were different trials with different populations, not head-to-head comparisons against Foundayo™, so treat the numbers as rough guideposts rather than a ranking. The summary of the current evidence: Foundayo™ trades some average weight loss for the convenience of a tablet with no injections and no food rules.
Who might care about a pill instead of an injection
- People with genuine needle aversion — the group most likely to delay or abandon treatment entirely.
- Frequent travelers, since there's no refrigeration, no sharps, and nothing to declare at security.
- People who value privacy — a tablet in a pill organizer is invisible in a way a weekly injection kit isn't.
Whether any GLP-1 medication — pill or injection — is appropriate for you is a clinical decision made with a licensed provider after reviewing your full history.
Can you get compounded orforglipron? (No — and be careful.)
As search interest in Foundayo™ grows, expect to see sellers offering "compounded orforglipron." Walk away. Orforglipron is a newly approved, patent-protected small molecule; it is not among the substances that US compounding pharmacies are permitted to use, and there is no legitimate compounded version. Anything sold as compounded or "research" orforglipron is a counterfeit red flag.
This is different from compounded semaglutide and tirzepatide, which licensed US compounding pharmacies may prepare per-patient when a prescriber documents a specific clinical need. Even then, compounded medications are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality — and the trial results above apply only to the FDA-approved products studied, not to compounded preparations.
Where Pallas fits
Pallas offers Foundayo™ at $299 for your first month, then $499 every 4 weeks (cash-pay; not billed to insurance), prescribed only when a US-licensed clinician determines it's appropriate for you after reviewing your intake. The same clinician can also prescribe the FDA-approved Wegovy® pill and the Wegovy®, Ozempic®, Zepbound® and Mounjaro® pens, or compounded semaglutide and tirzepatide, including a compounded oral semaglutide tablet, when one of those is the better fit. There's no membership fee, and nothing is charged unless a prescription is issued.
Bottom line: Foundayo™ (orforglipron) is real, FDA-approved, and a meaningful shift — the first take-anytime GLP-1 pill for weight management, with 11.1% average weight loss at the top dose in ATTAIN-1. It isn't available compounded, it isn't the same molecule as Wegovy® or Ozempic®, and Pallas now dispenses it cash-pay when a clinician prescribes it. If you're weighing your options, the right starting point is a licensed clinician who can look at your history and lay out what actually fits.
